Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Head and Neck Cancer

  Free Subscription

Articles published in Cancer

Retrieve available abstracts of 70 articles:
HTML format

Single Articles

    November 2022
  1. KOYUNCU CF, Nag R, Lu C, Corredor G, et al
    Image analysis reveals differences in tumor multinucleations in Black and White patients with human papillomavirus-associated oropharyngeal squamous cell carcinoma.
    Cancer. 2022;128:3831-3842.
    PubMed     Abstract available

    October 2022
  2. BROSE MS, Robinson BG, Sherman SI, Jarzab B, et al
    Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial.
    Cancer. 2022 Oct 19. doi: 10.1002/cncr.34493.
    PubMed     Abstract available

  3. JACKSON SS, Marks MA, Katki HA, Cook MB, et al
    Sex disparities in the incidence of 21 cancer types: Quantification of the contribution of risk factors.
    Cancer. 2022;128:3531-3540.
    PubMed     Abstract available

  4. Sharp rise in esophageal cancer and Barrett esophagus seen in middle-aged people.
    Cancer. 2022;128:3584-3585.

    August 2022
  5. LIN Y, Bruner DW, Paul S, Miller AH, et al
    A network analysis of self-reported psychoneurological symptoms in patients with head and neck cancer undergoing intensity-modulated radiotherapy.
    Cancer. 2022 Aug 15. doi: 10.1002/cncr.34424.
    PubMed     Abstract available

    July 2022
  6. MAZUL AL, Hartman CM, Mowery YM, Kramer JR, et al
    Risk and incidence of head and neck cancers in veterans living with HIV and matched HIV-negative veterans.
    Cancer. 2022 Jul 22. doi: 10.1002/cncr.34387.
    PubMed     Abstract available

  7. HSUEH CY, Lau HC, Huang Q, Gong H, et al
    Fusobacterium nucleatum impairs DNA mismatch repair and stability in patients with squamous cell carcinoma of the head and neck.
    Cancer. 2022 Jul 5. doi: 10.1002/cncr.34338.
    PubMed     Abstract available

    June 2022

  8. Erratum to "Remote triage incorporating symptom-based risk stratification for suspected head and neck cancer referrals: A prospective population-based study".
    Cancer. 2022 Jun 24. doi: 10.1002/cncr.34358.

  9. FAN JH, Wang JB, Yang H, Dawsey SM, et al
    Mortality after multivitamin supplementation: Nearly 35-year follow-up of the randomized Linxian Dysplasia Nutrition Intervention Trial.
    Cancer. 2022 Jun 7. doi: 10.1002/cncr.34344.
    PubMed     Abstract available

  10. O'BOYLE CJ, Siravegna G, Varmeh S, Queenan N, et al
    Cell-free human papillomavirus DNA kinetics after surgery for human papillomavirus-associated oropharyngeal cancer.
    Cancer. 2022;128:2193-2204.
    PubMed     Abstract available

    May 2022
  11. HUANG SH, Jacinto JCK, O'Sullivan B, Su J, et al
    Clinical presentation and outcome of human papillomavirus-positive nasopharyngeal carcinoma in a North American cohort.
    Cancer. 2022 May 19. doi: 10.1002/cncr.34266.
    PubMed     Abstract available

  12. NELSON TJ, Thompson CA, Zou J, Kumar A, et al
    Validation of NRG Oncology's prognostic nomograms for oropharyngeal cancer in the Veterans Affairs database.
    Cancer. 2022;128:1948-1957.
    PubMed     Abstract available

  13. COWZER D, Janjigian YY
    Top advances in esophageal/gastroesophageal junction cancers in 2021.
    Cancer. 2022;128:1894-1899.

  14. LI Y, Yao F, Jiao Z, Su X, et al
    Cyclin-dependent kinase 5 promotes the growth of tongue squamous cell carcinoma through the microRNA 513c-5p/cell division cycle 25B pathway and is associated with a poor prognosis.
    Cancer. 2022;128:1775-1786.
    PubMed     Abstract available

    April 2022
  15. KIYOTA N, Tahara M, Robinson B, Schlumberger M, et al
    Impact of baseline tumor burden on overall survival in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial.
    Cancer. 2022 Apr 5. doi: 10.1002/cncr.34181.
    PubMed     Abstract available

  16. HUTCHESON KA, Barbon CEA, Alvarez CP, Warneke CL, et al
    Refining measurement of swallowing safety in the Dynamic Imaging Grade of Swallowing Toxicity (DIGEST) criteria: Validation of DIGEST version 2.
    Cancer. 2022;128:1458-1466.
    PubMed     Abstract available

    March 2022
  17. PARK S, Oh D, Choi YL, Chi SA, et al
    Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
    Cancer. 2022 Mar 23. doi: 10.1002/cncr.34176.
    PubMed     Abstract available

  18. SOO J, Jin MC, Beadle BM, Holsinger FC, et al
    Circulating tumor DNA in head and neck cancer: Early successes and future promise.
    Cancer. 2022 Mar 17. doi: 10.1002/cncr.34189.
    PubMed     Abstract available

  19. CHUNG HC, Kang YK, Chen Z, Bai Y, et al
    Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients.
    Cancer. 2022;128:995-1003.
    PubMed     Abstract available

    February 2022
  20. EKANAYAKE WEERAMANGE C, Shu D, Tang KD, Batra J, et al
    Analysis of human leukocyte antigen associations in human papillomavirus-positive and -negative head and neck cancer: Comparison with cervical cancer.
    Cancer. 2022 Feb 17. doi: 10.1002/cncr.34148.
    PubMed     Abstract available

  21. OLIVER JR, Persky MJ, Wang B, Duvvuri U, et al
    Transoral robotic surgery adoption and safety in treatment of oropharyngeal cancers.
    Cancer. 2022;128:685-696.
    PubMed     Abstract available

  22. SCOTT-WITTENBORN N, D'Souza G, Tewari S, Rooper L, et al
    Prevalence of human papillomavirus in head and neck cancers at tertiary care centers in the United States over time.
    Cancer. 2022 Feb 8. doi: 10.1002/cncr.34124.
    PubMed     Abstract available

  23. SOUSA LG, Wang K, Torman D, Binks BJ, et al
    Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specified.
    Cancer. 2022;128:509-518.
    PubMed     Abstract available

    January 2022
  24. BALACHANDRA S, Eary RL, Lee R, Wynings EM, et al
    Substance use and mental health burden in head and neck and other cancer survivors: A National Health Interview Survey analysis.
    Cancer. 2022;128:112-121.
    PubMed     Abstract available

    December 2021
  25. LIANG L, Liu Z, Zhu H, Wang H, et al
    Efficacy and safety of thalidomide in preventing oral mucositis in patients with nasopharyngeal carcinoma undergoing concurrent chemoradiotherapy: A multicenter, open-label, randomized controlled trial.
    Cancer. 2021 Dec 15. doi: 10.1002/cncr.34074.
    PubMed     Abstract available

  26. WOTMAN MT, Miles BA, Bakst RL, Posner MR, et al
    A proposal for risk-based and strategy-adapted de-escalation in human papillomavirus-positive oropharyngeal squamous cell carcinoma.
    Cancer. 2021;127:4330-4338.

  27. AGGARWAL P, Hutcheson KA, Garden AS, Mott FE, et al
    Determinants of patient-reported xerostomia among long-term oropharyngeal cancer survivors.
    Cancer. 2021;127:4470-4480.
    PubMed     Abstract available

    October 2021
  28. TREISTER NS, Brennan MT, Sollecito TP, Schmidt BL, et al
    Exposed bone in patients with head and neck cancer treated with radiation therapy: An analysis of the Observational Study of Dental Outcomes in Head and Neck Cancer Patients (OraRad).
    Cancer. 2021 Oct 19. doi: 10.1002/cncr.33948.
    PubMed     Abstract available

  29. REN J, Pang W, Hueniken K, Haddad G, et al
    Longitudinal health utility and symptom-toxicity trajectories in patients with head and neck cancers.
    Cancer. 2021 Oct 1. doi: 10.1002/cncr.33936.
    PubMed     Abstract available

  30. FAKHRY C, Tewari SR, Zhang L, Windon MJ, et al
    RTOG-0129 risk groups are reproducible in a prospective multicenter heterogeneously treated cohort.
    Cancer. 2021;127:3523-3530.
    PubMed     Abstract available

    September 2021
  31. FOSTER CC, Couey MA, Kochanny SE, Khattri A, et al
    Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors.
    Cancer. 2021 Sep 21. doi: 10.1002/cncr.33780.
    PubMed     Abstract available

    Reply to Neoadjuvant chemotherapy for locoregionally advanced squamous cell carcinoma of the paranasal sinuses-Is it worthwhile?
    Cancer. 2021;127:3265.

  33. PANDA S, Raveendran S, Kumar R, Thakar A, et al
    Neoadjuvant chemotherapy for locoregionally advanced squamous cell carcinoma of the paranasal sinuses-Is it worthwhile?
    Cancer. 2021;127:3264.

  34. WU J, Xiao F, Zheng Y, Lin Y, et al
    Worldwide trend in human papillomavirus-attributable cancer incidence rates between 1990 and 2012 and Bayesian projection to 2030.
    Cancer. 2021;127:3172-3182.
    PubMed     Abstract available

  35. RYAN WR, Xu MJ, Ochoa E, Plonowska-Hirschfeld KA, et al
    Oncologic outcomes of human papillomavirus-associated oropharynx carcinoma treated with surgery alone: A 12-institution study of 344 patients.
    Cancer. 2021;127:3092-3106.
    PubMed     Abstract available

  36. ABDELMEGUID AS, Silver NL, Boonsripitayanon M, Glisson BS, et al
    Role of induction chemotherapy for oral cavity squamous cell carcinoma.
    Cancer. 2021;127:3107-3112.
    PubMed     Abstract available

    August 2021
  37. SEAMAN AT, Seligman KL, Nguyen KK, Al-Qurayshi Z, et al
    Characterizing head and neck cancer survivors' discontinuation of survivorship care.
    Cancer. 2021 Aug 30. doi: 10.1002/cncr.33888.
    PubMed     Abstract available

  38. HARDMAN JC, Tikka T, Paleri V
    Remote triage incorporating symptom-based risk stratification for suspected head and neck cancer referrals: A prospective population-based study.
    Cancer. 2021 Aug 19. doi: 10.1002/cncr.33800.
    PubMed     Abstract available

  39. GUO TW, Saiyed F, Yao CMKL, Kiong KL, et al
    Outcomes of patients with oropharyngeal squamous cell carcinoma treated with induction chemotherapy followed by concurrent chemoradiation compared with those treated with concurrent chemoradiation.
    Cancer. 2021;127:2916-2925.
    PubMed     Abstract available

  40. CHERA BS, Sheth SH, Patel SA, Goldin D, et al
    Phase 1 trial of adavosertib (AZD1775) in combination with concurrent radiation and cisplatin for intermediate-risk and high-risk head and neck squamous cell carcinoma.
    Cancer. 2021 Aug 11. doi: 10.1002/cncr.33789.
    PubMed     Abstract available

  41. AMIT M, Liu C, Mansour J, Gleber-Netto FO, et al
    Elective neck dissection versus observation in patients with head and neck cutaneous squamous cell carcinoma.
    Cancer. 2021 Aug 6. doi: 10.1002/cncr.33773.
    PubMed     Abstract available

  42. SCHRANK TP, Lenze N, Landess LP, Hoyle A, et al
    Genomic heterogeneity and copy number variant burden are associated with poor recurrence-free survival and 11q loss in human papillomavirus-positive squamous cell carcinoma of the oropharynx.
    Cancer. 2021;127:2788-2800.
    PubMed     Abstract available

    July 2021
  43. YU KJ, Hsu WL, Chiang CJ, Chen TC, et al
    Cancer patterns in nasopharyngeal carcinoma multiplex families over 15 years.
    Cancer. 2021 Jul 29. doi: 10.1002/cncr.33799.
    PubMed     Abstract available

  44. ROMESSER PB, Sherman EJ, Whiting K, Ho ML, et al
    Intensity-modulated radiation therapy and doxorubicin in thyroid cancer: A prospective phase 2 trial.
    Cancer. 2021 Jul 22. doi: 10.1002/cncr.33804.
    PubMed     Abstract available

  45. VAN DIJK LV, Mohamed ASR, Ferrarotto R, McCoy LA, et al
    The impact of induction and/or concurrent chemoradiotherapy on acute and late patient-reported symptoms in oropharyngeal cancer: Application of a mixed-model analysis of a prospective observational cohort registry.
    Cancer. 2021;127:2453-2464.
    PubMed     Abstract available

  46. WHITMARSH A, Pring M, Thomas SJ, Waylen A, et al
    Survival advantage in patients with human papillomavirus-driven oropharyngeal cancer and variation by demographic characteristics and serologic response: Findings from Head and Neck 5000.
    Cancer. 2021;127:2442-2452.
    PubMed     Abstract available

  47. XIAO Q, Kitahara CM
    Reply to associations between light at night and risk of thyroid cancer.
    Cancer. 2021 Jul 10. doi: 10.1002/cncr.33685.

  48. XIAO P, Li L, Ding S, Xie J, et al
    Associations between light at night and risk of thyroid cancer.
    Cancer. 2021 Jul 10. doi: 10.1002/cncr.33686.

  49. LIU Z, Li H, Yu KJ, Xie SH, et al
    Comparison of new magnetic resonance imaging grading system with conventional endoscopy for the early detection of nasopharyngeal carcinoma.
    Cancer. 2021 Jul 7. doi: 10.1002/cncr.33552.
    PubMed     Abstract available

    June 2021
  50. FU TS, Scheffler P, Forner D, Noel CW, et al
    A cost-utility analysis comparing CT surveillance, PET-CT surveillance, and planned postradiation neck dissection for advanced nodal HPV-positive oropharyngeal cancer.
    Cancer. 2021 Jun 1. doi: 10.1002/cncr.33653.
    PubMed     Abstract available

  51. SABA NF
    Preoperative chemotherapy for sinonasal squamous cell carcinoma (SNSCC): Time to move closer to a definitive answer.
    Cancer. 2021;127:1734-1735.

  52. ABDELMEGUID AS, Teeramatwanich W, Roberts DB, Amit M, et al
    Neoadjuvant chemotherapy for locoregionally advanced squamous cell carcinoma of the paranasal sinuses.
    Cancer. 2021;127:1788-1795.
    PubMed     Abstract available

    May 2021
  53. RUAN X, Liang JH, Pan Y, Cai R, et al
    Apatinib for the treatment of metastatic or locoregionally recurrent nasopharyngeal carcinoma after failure of chemotherapy: A multicenter, single-arm, prospective phase 2 study.
    Cancer. 2021 May 27. doi: 10.1002/cncr.33626.
    PubMed     Abstract available

  54. XIAO C, Beitler JJ, Peng G, Levine ME, et al
    Epigenetic age acceleration, fatigue, and inflammation in patients undergoing radiation therapy for head and neck cancer: A longitudinal study.
    Cancer. 2021 May 24. doi: 10.1002/cncr.33641.
    PubMed     Abstract available

  55. JUNG YS, Seok J, Hong S, Ryu CH, et al
    The emergence of oral cavity cancer and the stabilization of oropharyngeal cancer: Recent contrasting epidemics in the South Korean population.
    Cancer. 2021;127:1638-1647.
    PubMed     Abstract available

  56. SHANMUGAM A, Hariharan AK, Hasina R, Nair JR, et al
    Ultrasensitive detection of tumor-specific mutations in saliva of patients with oral cavity squamous cell carcinoma.
    Cancer. 2021;127:1576-1589.
    PubMed     Abstract available

  57. WEISS JM
    Surgery alone for transorally resected human papillomavirus-driven head and neck cancer-Can we de-intensify adjuvant therapy to 0 Gy and 0 mg/m(2) ?
    Cancer. 2021 May 6. doi: 10.1002/cncr.33610.
    PubMed     Abstract available

    April 2021
  58. DAHLSTROM KR, Song J, Thall PF, Fuller CD, et al
    Conditional survival among patients with oropharyngeal cancer treated with radiation therapy and alive without recurrence 5 years after diagnosis.
    Cancer. 2021;127:1228-1237.
    PubMed     Abstract available

  59. CHEN Y, Chang ET, Liu Q, Cai Y, et al
    Occupational exposures and risk of nasopharyngeal carcinoma in a high-risk area: A population-based case-control study.
    Cancer. 2021 Apr 6. doi: 10.1002/cncr.33536.
    PubMed     Abstract available

    Racial disparity in head and neck cancer.
    Cancer. 2021 Apr 2. doi: 10.1002/cncr.33555.

  61. VOORA RS, Kotha NV, Kumar A, Qiao EM, et al
    Association of Race and Health Care System With Disease Stage and Survival in Veterans With Larynx Cancer.
    Cancer. 2021 Apr 2. doi: 10.1002/cncr.33557.
    PubMed     Abstract available

  62. DRAKE VE, Fakhry C, Windon MJ, Stewart CM, et al
    Timing, number, and type of sexual partners associated with risk of oropharyngeal cancer.
    Cancer. 2021;127:1029-1038.
    PubMed     Abstract available

    March 2021
  63. BALACHANDRA S, Kusin SB, Lee R, Blackwell JM, et al
    Blood-based biomarkers of human papillomavirus-associated cancers: A systematic review and meta-analysis.
    Cancer. 2021;127:850-864.
    PubMed     Abstract available

    February 2021
  64. HO AS, Luu M, Kim S, Tighiouart M, et al
    Nodal staging convergence for HPV- and HPV+ oropharyngeal carcinoma.
    Cancer. 2021 Feb 17. doi: 10.1002/cncr.33414.
    PubMed     Abstract available

  65. CAMPBELL BR, Chen Z, Faden DL, Agrawal N, et al
    The mutational landscape of early- and typical-onset oral tongue squamous cell carcinoma.
    Cancer. 2021;127:544-553.
    PubMed     Abstract available

  66. ZHANG D, Jones RR, James P, Kitahara CM, et al
    Associations between artificial light at night and risk for thyroid cancer: A large US cohort study.
    Cancer. 2021 Feb 8. doi: 10.1002/cncr.33392.
    PubMed     Abstract available

  67. YIP L, Gooding WE, Nikitski A, Wald AI, et al
    Risk assessment for distant metastasis in differentiated thyroid cancer using molecular profiling: A matched case-control study.
    Cancer. 2021 Feb 4. doi: 10.1002/cncr.33421.
    PubMed     Abstract available

  68. STRACHNA O, Cohen MA, Allison MM, Pfister DG, et al
    Case study of the integration of electronic patient-reported outcomes as standard of care in a head and neck oncology practice: Obstacles and opportunities.
    Cancer. 2021;127:359-371.
    PubMed     Abstract available

    January 2021
  69. ALHUMAIDI H, Manochakian R, Cochuyt J, Chindris A, et al
    Initial treatment of patients with thyroid cancer: Outcomes and factors associated with care at academic versus nonacademic cancer centers.
    Cancer. 2021 Jan 15. doi: 10.1002/cncr.33408.
    PubMed     Abstract available

    June 2020
  70. BROUGHMAN JR, Xiong DD, Moeller BJ, Contrera KJ, et al
    Rethinking the 10-pack-year rule for favorable human papillomavirus-associated oropharynx carcinoma: A multi-institution analysis.
    Cancer. 2020;126:2784-2790.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Head and Neck Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.